Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GBS NN

X
Drug Profile

GBS NN

Alternative Names: GBS NN/NN2; GBS vaccine - Minervax; GBS-NN/NN2 vaccine; Group B Streptococcal vaccine - Minervax; Streptococcal B vaccine - Minervax

Latest Information Update: 18 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Lund University
  • Developer Minervax
  • Class Streptococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Streptococcal infections

Most Recent Events

  • 10 Jul 2024 Minervax ApS plans to initiate a phase II/III trial for Streptococcus Agalactiae Infection (In volunteers) in 2024 (IM) (NCT06494475)
  • 23 May 2024 Minervax completes a phase I trial in Streptococcal infections (Prevention, In the elderly) in Belgium (IM) (NCT05782179)
  • 18 Oct 2023 MinervaX completes a phase II trial in Streptococcal infections (In infants, In adults, In neonates, Prevention) in Denmark, South Africa and United Kingdom (IM) (NCT05154578)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top